Thursday, June 26, 2008

How's that for Genomic Medicine by Press Release?


Warfarin......what a horrible drug!
I have seen people require trasfusions, special clotting factors, surgery. I have even seen people die at the hands of this medication. How can we tame the beast????

FOR IMMEDIATE RELEASE
Contact
Jonathan Freed, Chief Community OfficerHelix Health of Connecticut, PLLC(888) 584-8999(212) 918-9394 fax
webcasts@helixhealthofconnecticut.org or visit our website http://www.helixhealthofconnecticut.org/

One in four patients who receive anticoagulant therapy (warfarin) experience bleeding events.

Join Dr. Steven Murphy, Dr. Gary Marchant and a panel of medical, scientific and legal experts in a 90-minute Helix Health of Connecticut CliniCast(TM) on genetic testing, genomic medicine and the science of accurate warfarin dosing.

Greenwich, CT, June 23, 2008 — Helix Health of Connecticut, the first U.S. stand-alone genomic medicine practice, is hosting a 90-minute CliniCast(TM) this Monday, June 30, 2008 from 1:00-2:30 PM EDT to examine:

How Genomic Medicine Improves the Accuracy of Warfarin Dosing

Registration
To register, point your browser here:
http://event.netbriefings.com/event/helixhealthofconnecticut/register.html


There is a growing number of patients taking warfarin (also known under the brand names of Coumadin®, Jantoven®, Marevan®, and Waran®) who are not willing to take the risk of experiencing a bleeding event from their medication, and they are undergoing genetic testing to discover and to understand what they must do to manage these risks. Knowing a patient’s genes may significantly aid in initial warfarin dosing.

Webcast topics:


1. Why genetic testing is a necessary feature in anticoagulant therapy.
2. What potential risks exist in “Trial and Error” Dosing
3. Will insurance cover this genetic testing?
4. What are potential tort issues in predictive genetic testing and medical uses of genetic tests associated with anticoagulant therapy?
5. Why aren't physicians utilizing FDA approved testing and dosage guidance?


Panel:
Steven A.R. Murphy, MD - Clinical Genetics Fellow at Yale School of Medicine, and Helix Health of Connecticut's Managing Partner will moderate the panel.


Adam J. Messenger, MD - Specializing in the fields of Pharmacogenomics and Pharmacogenetics, which strive to select the correct medication and the correct dosage of that medication based on an individual’s genetic blueprint. Currently on faculty at New York Medical College and at the Graduate School of Basic Medical Sciences in the Department of Pharmacology.


Glenn Gandelman, MD, MPH, FACC - Cardiologist specializing the diagnosis, prevention, and treatment of cardiovascular disease. Managing Partner, Gandelman Cardiology, PC, Greenwich, CT. Additional training in echocardiography and nuclear medicine. Board certified in Internal Medicine, Cardiology, Echocardiography, and Nuclear Cardiology. Also prominent blogger and writer for the New York Times website About.com. Glenn wirtes for heartattacks.about.com


Eric Johnson, PhD - Chief Science Officer Iverson Genetic Diagnostics, Inc. Director of the Neurovascular/Epilepsy Genetics Research Laboratory at the Barrow Neurological Institute (BNI) in Phoenix, AZ and as Founding Director of the clinical Molecular Diagnostics and BioBanking Laboratories at PreventionGenetics in Marshfield, WI.


Gary E. Marchant – PhD, JD, Lincoln Professor of Emerging Technologies, Law & Ethics, Sandra Day O'Connor College of Law; Executive Director, Center for Law, Science & Technology, Professor, School of Life Sciences Arizona State University.

Registration

Registration is limited, so please register soon.
If you are unable to attend, a podcast of the session will be available on the Helix Health of Connecticut's website.
http://www.helixhealthofconnecticut.org/



About Helix Health of Connecticut/NYC, PLLC/LLC — a medical practice that is bringing genomic medicine to health care. With offices in Greenwich, CT and New York, NY, offers patients and their physicians expertise in genomic medicine and provides the tools required to take full advantage of genetic testing.





To view our May 21st CliniCastTM on Genomic Medicine and the Management of Breast and Ovarian Cancer, visit http://event.netbriefings.com/event/helixhealthofconnecticut/Archives/genomic/
Register now....we have registrants from Harvard, Cleveland Clinic, Yale, 23anMe, DNADirect, Navigenics, Mayo, Affymetrix, Iverson, 454/Roche, DNAGenotek, Broad, New York Times, LA Times............Come join the fun!!!


The Sherpa Says:

Have been busy with AG....who is demanding more of my time lately....So I decided to pull a "science by press release move"......whaddya think? In all seriousness, please sign up for the CliniCast(TM) It promises to be one of the best....especially in this time of regulation.....because litigation always follows regulation.........

No comments: